RecruitingPhase 4NCT05935358

Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study

Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study (NuPOWER)

Sponsor

Octapharma

Enrollment

28 participants

Start Date

Nov 28, 2023

Study Type

INTERVENTIONAL

Conditions

Severe Hemophilia A

Summary

Recombinant factor VIII for the prevention of bleeding in patients with severe haemophilia A undergoing major surgery while receiving emicizumab prophylaxis

Eligibility

Sex: MALEMin Age: 12 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Nuwiq for people with severe hemophilia a. The study is currently recruiting participants at 18 locations. People eligible for this study include men aged 12 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGNuwiq

Nuwiq is a purified B-domain-deleted FVIII glycoprotein synthesised by a genetically engineered human embryonic kidney cell line (HEK 293F).

Locations(18)

UT Southwestern Medical Center

Dallas, Texas, United States

University Hospital Centre Zagreb

Zagreb, Croatia

Helsinki University Hospital

Helsinki, Finland

CHU de Nantes Hôtel-Dieu

Nantes, France

CHRU de Tours

Tours, France

Vivantes Klinikum im Friedrichshein (KFH)

Berlin, Germany

Gerinnungszentrum Rhein-Ruhr

Duisburg, Germany

Universitätsklinikum Hamburg Eppendorf (UKE)

Hamburg, Germany

Christian Medical College Vellore

Vellore, Tamil Nadu, India

St. John's Medical College Hospital

Bengaluru, India

Azienda Ospedaliera Pugliese Ciaccio

Catanzaro, Italy

Azienda Ospedaliero Universitaria Careggi - Centro Emofilia

Florence, Italy

Centro Trombosi e Malattie Emorragiche, ITCCS Humanitas Research Hospital

Milan, Italy

Centre for Haemopilia, Institute for transfusion medicine of Republic of North Macedonia

Skopje, North Macedonia

Clinical Center for Serbia Belgrade

Belgrade, Serbia

Hospital Universitario La Paz

Madrid, Spain

Hospital Universitario Virgen del Rocio

Seville, Spain

St. James's University Hospital

Leeds, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05935358

Related Trials

Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.

NCT0768489819 locations

Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment

NCT0766390324 locations

A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.

NCT067036067 locations

Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein

NCT0614255228 locations

Dynamics of the Anti-factor VIII Antibody Signature During Treatment With Emicizumab

NCT058028361 location